Arsenal Bio: Cutting Staff by Half, Not Cells
Arsenal Bio, one of the rare cell therapy companies still swimming in a sea of failed raises, just laid off nearly half its staff. In a sector where funding looks like a unicorn spotted only in biotech myths, Arsenal Bio managed to raise some capital before executing a harsh 50% staff cull. Itâs like hosting a party because you found chips, then eating all the guests. This bittersweet survival dance highlights the brutal biotech winter, reminding us that while cells might fight disease, companies clearly donât fight layoffs. Half the team out, capital precious: Arsenal Bioâs 2024 cell saga, minus the happy ending.
Share the Story
When your company is 'one of the few able to raise funds' but still chops half your team, your business model is basically survival-of-the-fittest meets corporate Hunger Games.
Arsenal Bio raised cash but still slashed half the staff. Nothing says 'biotech innovation' like 'hope you like unemployment.'
Cell therapy startup Arsenal Bio proves even in science, youâre half as likely to keep your job as to get stem cells.
Source: Statnews | Published: 9/17/2025 | Author: Jason Mast
More Articles in Business
Pentagon Brings Tech Bros to War Room, Still Confused About AI's Consciousness
Politico Announces Australia Launch for 2026, Because Why Not Start Late?
Trump Promises Retirement Plan That Matches Generosity of Federal Workersâ Excuses
Workday CEO Wonders Who to Replace with AI Before Deciding to Lay Off 400 Humans
David Ellisonâs 10th WBD Offer: Slightly Better Than Doing Nothing
AI Slaps White-Collar Jobs, Blue-Collars Brace for Gig Economy Chain Reaction
Costco, Toyota & FedEx Sue Trump For Tariff Refunds Like Itâs Black Friday Cashback
Lamborghini Cancels Silent EV, Citing Absence of Vroom-Feelz
